Alzheimer’s Disease (AD) diagnosis is based on a cognitive impairment evaluation alongside a brain amyloid deposits estimation through measurements of Aβ42/40 peptides and/or p-tau protein in cerebrospinal fluid (CSF) or by positron emission tomography (PET) imaging (1). Here, MAPT is linked to Cognitive impairment.